Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
0
Authors
Luís Paz-Ares
38 more
Luís Paz-Ares
•
Suresh Ramalingam
36 more
•
Martin Reck
Published
October 13, 2021
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Thoracic Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Nivolumab
Confidence Interval
Show all topics
DOI
10.1016/j.jtho.2021.09.010
License
CC-BY-NC-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Thoracic Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Nivolumab
Confidence Interval
Show all topics
DOI
10.1016/j.jtho.2021.09.010
License
CC-BY-NC-ND
Other Formats
PDF
